CCNE1 and ovarian carcinoma: Noteworthy, the gain at 19q12 was associated with genomic instability and poorer survival in ovarian cancer patients (42), and the amplification of CCNE1 has been found as a discriminating biomarker for first-line platinum-based chemotherapy.